Skip to content
Search

Latest Stories

Margaret MacRury steps down as Rowlands superintendent after a decade of service

Margaret MacRury has stepped down from her role as superintendent director for the Rowlands Pharmacy, which has a community pharmacy network in England, Scotland and Wales with more than 450 branches.

MacRury, who served the role for a decade, will step down next month to focus on the pharmacy contract developments taking place in Scotland, Rowlands said in a statement.


She will start her new role in February 2022.

With MacRury leaving the position, Stephen Thomas, currently her deputy, will take up the role of superintendent for Rowlands. He has been with the multiple for nearly 18 years and has worked side-by-side with MacRury for the last decade.

MacRury stated: “I know Stephen will continue that commitment to protecting patients and promoting the pharmacy sector.

“During my time as superintendent director I have seen our sector ever increasingly being recognized as a critical part of the NHS “family” providing essential access to much-needed healthcare support and advice alongside dispensing. These are exciting times which Stephen will take forward.

“I believe that the Scottish government understands the unique value of community pharmacy in delivering improved healthcare outcomes. Going forward, I will continue to play my part, alongside Stephen, in promoting community pharmacy not just in Scotland, but throughout Great Britain.”

Stephen Thomas Stephen Thomas

On acquiring new role, Thomas stated: “Our sector faces many challenges, but also new opportunities. Community pharmacy is the third pillar of our national healthcare service alongside GP surgeries and hospitals. With fair and sustainable funding it can, and does, transform lives.

“PHOENIX will continue to pioneer innovative healthcare provision such as bricks & clicks, blending physical and digital services, whilst at all times putting the patient at the heart of what we do.”

Rowland is a division of PHOENIX Group, which is one of Europe’s largest and integrated pharmaceutical providers, offering wholesale, retail and pharma services.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less